On September 25, 2025, the FDA approved Inluriyo (imlunestrant) for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. This video explores the breakthrough, including clinical data from the EMBER-3 trial, as well as patient eligibility and dosing guidelines.
More Videos in ESR1 Mutated ER HER2 Advanced Breast Cancer Content Hub
Aditya Bardia, MD, MPH, director of translational research integration, UCLA, explains how metastatic estrogen receptor-positive breast cancers can develop ESR1 mutations. Donald McDonnell, PhD, research scientist, Duke University,…
Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Suzanne A. W. Fuqua, PhD, Baylor College of Medicine, explains that while the role of ESR1 mutations in primary breast cancer remains controversial, earlier studies have reported specific…
In this video, Virginia Kaklamani, MD, UT Health San Antonio, Texas, reviews the results of the EMBER-3 Phase 3 trial of imlunestrant, an oral SERD, in patients with…
Patrick Neven, MD, Universitair Ziekenhuis Leuven, Leuven, Belgium, presents data from the EMBER-2 window-of-opportunity study, in which imlunestrant was given for about 2 weeks before surgery in women…
In this podcast, hosts Drs. Rahul and Rohit Gosain, and Jame Abraham, MD, Cleveland Clinic, highlight findings from the EMBER-3 study comparing imlunestrant alone versus imlunestrant combined with…
In an interview that took place at the European Society for Medical Oncology 2024 Congress in Barcelona, Spain, Timothy Yap, MBBS, PhD, medical oncologist, The University of Texas…
In this video, Aditya Bardia, MD, MPH, Massachusetts General Hospital, and Donald McDonnell, PhD, Duke University, explain that ESR1 mutations often arise in metastatic, hormone-receptor positive breast cancers…
Matthew P. Goetz, MD, Mayo Clinic, Rochester, Minnesota, describes how resistance to endocrine therapy often develops in ER-positive breast cancer through emergence of ESR1 mutations, which occur in…
This webinar, focused on challenging cases in metastatic breast cancer, was moderated by Ashkan Lashkari, MD, oncologist at Wellness Oncology, California, and included expert panelists Rebecca A. Shatsky,…
